$ 3.82
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a...
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is 'cheap' on EV/EBITDA.
Target Price
The average target price of ANRO is 10 and suggests 172% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
